文献速递妇科

I期黏液性卵巢癌的长期生存结局——一种预测化疗获益的临床计算器

Long term survival outcomes of stage I mucinous ovarian cancer - A clinical calculator predictive of chemotherapy benefit.
PubMed 文献 · Gynecol Oncol · 2020-08-20

基于美国国家癌症数据库2004至2014年2041例I期黏液性卵巢癌患者,用Cox回归建立10年生存预后评分。未调整10年生存率化疗组81%对未化疗组79%(P=0.46)。低风险组死亡风险无显著差异(HR=0.80),高风险组化疗与更低死亡风险相关(HR=1.58)。

要点

  • I期黏液性卵巢癌中67%为IA/IB期,29%为IC期,36%接受辅助化疗。
  • 未调整10年生存率化疗组81% vs 未化疗组79%,差异无统计学显著(P=0.46)。
  • 预测评分高风险组中,未化疗死亡风险高于化疗(HR=1.58,95%CI 1.05-2.38,P=0.03)。

核心结论

  • 预测评分算法可能提供长期生存的预后信息,并识别可能从辅助化疗中获得生存获益的高风险I期黏液性卵巢癌患者。

研究设计与样本

  • 数据来自美国国家癌症数据库2004至2014年,纳入2041例符合条件的I期黏液性卵巢癌患者,基于人口学和手术特征用Cox回归开发10年生存预后评分系统。

主要发现

  • 2041例中IA/IB期1362例(67%),IC期598例(29%),I期未特指81例(4%);中位年龄52岁(范围13-90岁);737例(36%)接受辅助化疗。
  • IC期较IA/IB期辅助化疗更常见(69% vs 21%,P<0.001),低分化较低分化更常见(69% vs 23%,P<0.001)。
  • 未调整10年生存率化疗组81% vs 未化疗组79%,差异无统计学显著(P=0.46)。
  • 低风险组未化疗 vs 化疗死亡风险相似(88% vs 84%;HR=0.80,95%CI=0.56-1.15,P=0.23)。
  • 高风险组未化疗 vs 化疗死亡风险更高(51% vs 74%;HR=1.58,95%CI=1.05-2.38,P=0.03)。

关键数值与推荐

  • 多变量Cox回归模型纳入年龄、分期、分级、淋巴血管间隙浸润和腹水预测低风险或高风险死亡。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine the long-term potential benefit of adjuvant chemotherapy in subgroups of high-risk stage I mucinous ovarian cancer patients using a predictive scoring algorithm. METHODS: Data were collected from the National Cancer Database from 2004 to 2014. Based on demographic and surgical characteristics, a novel 10-year survival prognostic scoring system was developed using Cox regression. RESULTS: There were 2041 eligible patients with stage I mucinous ovarian cancer including 1362 (67%) with stage IA/IB disease, 598 (29%) with stage IC disease, and 81 (4%) with stage I disease not otherwise specified. Median age was 52 with a range of 13-90 years old. 737 (36%) patients were treated with adjuvant chemotherapy. Adjuvant chemotherapy was more common in patients with stage IC relative to stage IA/IB disease (69% vs. 21%, P < 0.001) or with poorly-differentiated relative to well-differentiated tumors (69% vs. 23%, P < 0.001). Unadjusted 10-year survival was 81% relative to 79% for patients treated with vs. without chemotherapy, respectively (P = 0.46). Patients were predicted to exhibit a low- or a high-risk of death using a multivariate Cox regression model with age, stage, grade, lymphovascular space invasion and ascites. Risk of death without vs. with adjuvant chemotherapy was similar in low-risk patients (88% vs. 84%; HR = 0.80, 95%CI = 0.56-1.15, P = 0.23) and worse in high-risk patients (51% vs. 74%; HR = 1.58, 95%CI: 1.05-2.38, P = 0.03) with stage I mucinous ovarian cancer. CONCLUSIONS: A predictive scoring algorithm may provide prognostic information on long-term survival and identify high-risk stage I mucinous ovarian cancer patients who might achieve a survival benefit from adjuvant chemotherapy.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Richardson MT, Mysona DP, Klein DA, et al. Long term survival outcomes of stage I mucinous ovarian cancer - A clinical calculator predictive of chemotherapy benefit. Gynecol Oncol. 2020. PMID: 32828578. doi:10.1016/j.ygyno.2020.07.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。